(NASDAQ: ALXO) Alx Oncology Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.08%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.12%.
Alx Oncology Holdings's earnings in 2026 is -$88,868,000.On average, 8 Wall Street analysts forecast ALXO's earnings for 2026 to be -$105,228,201, with the lowest ALXO earnings forecast at -$130,552,942, and the highest ALXO earnings forecast at -$91,839,191. On average, 8 Wall Street analysts forecast ALXO's earnings for 2027 to be -$95,162,895, with the lowest ALXO earnings forecast at -$108,134,760, and the highest ALXO earnings forecast at -$76,297,174.
In 2028, ALXO is forecast to generate -$83,267,533 in earnings, with the lowest earnings forecast at -$94,947,594 and the highest earnings forecast at -$76,297,174.